By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.
For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.
Read our latest news
What is Paclitaxel (Taxol) and how does it work? Paclitaxel, perhaps better known by its brand name Taxol, has long been used as a chemotherapy drug and has been used to treat numerous types of cancer . It is a cytoskeletal drug, which binds to a specific site on...
In November 2020 Nanolive attended the Spanish & Portuguese Advanced Optical Microscopy (SPAOM) meeting, held remotely from Valencia in Spain. The objective of this annual congress is to keep new researchers in the Iberian Peninsula at the forefront of optical...
Webinar: Label-free cytotoxicity assays: do different cell death stimuli show unique signatures in cell metrics?
In this webinar, Dr. Emma Gibbin-Lameira, Communications Specialist at Nanolive reveals how Nanolive imaging can be used to conduct real-time, automated cytotoxicity assays, without the contribution of photo and cytotoxic methodological artefacts. Specifically, she...
Automated live cell imaging: a unique walk-away solution for long-term live cell imaging of single cells and cell populations
3D CELL EXPLORER-fluo
Multimodal Complete Solution: combine high quality non-invasive 4D live cell imaging with fluorescence